Annual Press Conference Stuttgart, Germany, 13 December 2012

Transcription

1 Annual Press Conference Stuttgart, Germany, Dr. Michael Kaschke President and CEO Thomas Spitzenpfeil Chief Financial Officer

2 Dr. Michael Kaschke President and CEO Thomas Spitzenpfeil Chief Financial Officer 2

3 Fiscal year 2011/12 at a glance in EUR million Revenue EBIT (Earnings before Interest and Taxes) Earnings FY 2011/12 FY 2010/11* 4,163 4, Change 2% -188m euros -144m euros 30 SEP SEP 2011* Employees 24,326 23,426 4% *The previous year's figures were adjusted due both to the classification of the Security and Defense Systems strategic business unit as a discontinued operation (IFRS 5) and to the changed method of valuating provisions for pensions. 3

4 Revenue distribution Globally successful 88% generated outside Germany Collaborations 899m -20% EMEA 1,398m 7%* Americas 1,056m 3%* *Adjusted for currency influences/calculated on a like-for-like basis. APAC 810m 10%* 4

5 Semiconductor Manufacturing Technology business group Expected cyclical decline 1,181 1,040 Revenue 967 million -18% - High development expenditure for EUV affects earnings EUV milestone: first complete module delivered to ASML EUV will be the driver for significant energy savings Number of employees increased by 22% despite decline in revenue 2009/ / /12 Prior year's figures likefor-like excluding electron microscopy 5

6 Industrial Metrology business group Dynamic growth at high level Revenue / / / million 26% Customers positive about broad product portfolio Market share gained through global system solutions Third production site outside Germany after USA and China opened in Bangalore, India Number of employees increased by 12% 6

7 Microscopy business group Position in difficult environment maintained Revenue 650 million 5% - BioScience research feeling noticeable budget cuts Materials microscopy performing extraordinarily well Correlative microscopy accepted by customers Number of employees increased by 9% 2009/ / /12 Prior year's figures likefor-like including electron microscopy 7

8 Medical Technology business group Sustained dynamic development with strong growth in Asia Revenue 984 million 15% 2009/ / /12 Growth considerably outpaced market in all areas Focus on Asia on-site development for middle market segment 100 Years of Medical Technology Number of employees increased by 8% The values deviate from the published figures of Carl Zeiss Meditec AG as a result of different consolidation models. 8

9 Vision Care business group Restructuring after 100% acquisition taking hold Revenue 860 million 1% 2009/ / /12 Winner in patent dispute about freeform technology; multi-year licensing agreement with competitors Production and sales network optimized around the world - Number of employees decreased by 4% 9

10 Camera Lens, Sports Optics, Planetariums strategic business units Opportunities with innovations on growth markets used 160 Revenue million 11% 2009/ / /12 Camera Lenses with innovation fireworks at 2012 photokina Good growth in Sports Optics Planetariums open up new markets, including Sri Lanka Number of employees unchanged 10

11 Additional financial highlights for 2011/12 11

12 Investments in property, plant and equipment Investment amount almost doubled 289 million 129 million Investments in property, plant and equipment Depreciation of property, plant and equipment 2009/ /11* 2011/12 *The previous year's figures were adjusted due both to the classification of the Security and Defense Systems strategic business unit as a discontinued operation (IFRS 5) and to the changed method of valuating provisions for pensions. 12

13 Building for the future: look at current projects (Germany) New construction of a development, administrative and production facility for Medical Technology Expansion of office space for Semiconductor Manufacturing Technology, featuring new company restaurant Construction of a cogeneration unit, Oberkochen New construction of logistics center, Oberkochen-Königsbronn 13

14 Building for the future: look at current projects (outside Germany) Campus in Bangalore, India Rooftop solar panels in Dublin, California 14

15 Investments in research and development 9% of revenues for record investments million 14% 2009/ /11* 2011/12 *The previous year's figures were adjusted due both to the classification of the Security and Defense Systems strategic business unit as a discontinued operation (IFRS 5) and to the changed method of valuating provisions for pensions. 15

16 Economic Value Added Goal achieved; triple-digit increase in corporate value 134 million Increased EVA despite higher investments 16

17 Free cash flow Cash flow characterized by positive EBIT and high investments million million 2009/10* 2010/11* 2011/12 *The previous year's figures were adjusted due both to the classification of the Security and Defense Systems strategic business unit as a discontinued operation (IFRS 5) and to the changed method of valuating provisions for pensions. 17

18 Financial strength Strong cash flows for record investments without loss of substance million -6% 71 Gross cash Net cash 1 OCT 2010* 30 SEP SEP 2010 *From this date full consolidation of Carl Zeiss Vision. 18

19 Equity 26% equity ratio despite increasing pension provisions 1,150 1,164 1,213 million 4% 30 SEP 2010* 30 SEP 2011* 30 SEP *The previous year's figures were adjusted due both to the classification of the Security and Defense Systems strategic business unit as a discontinued operation (IFRS 5) and to the changed method of valuating provisions for pensions. 19

20 Forecast for the business groups Semiconductor Manufacturing Technology Further downward trend in the market for semiconductor equipment, recovery dependent on consumer behavior in PC segment Industrial Metrology Dynamic growth of the past two years will slow still potential in new markets Microscopy National debt crisis impacts government spending focus on rapidly developing economies and industrial materials microscopy Medical Technology Demographic trend creates good environment for further growth but partially declining healthcare expenditure in developing markets Vision Care Continuation of course of growth in established markets focused activities in dynamic economies 20

21 Overall forecast for 2012/13 Good foundation Order backlog of around 4.2 billion euros Carl Zeiss is a very healthy company Ambitious goals in a difficult environment Revenue of around 4 billion euros Carl Zeiss is unwavering in its pursuit of investment course and Agenda 2016 Strong portfolio ensures balance Signals from most business groups remain positive 21

22 Contact If you have any questions, please do not hesitate to contact Jörg Nitschke Corporate Communications Phone 49 (0) 7364/

23